Dr. Young is BeiGene’s Acting Head of Medicinal Chemistry.

Dr. Young has deep and broad experience in medicinal chemistry and pharmaceutical R&D, having developed compounds across a wide range of therapeutic areas. He led the chemistry research teams that delivered widely prescribed HIV drugs efavirenz and raltegravir. He previously served as the Vice President of Basic Research and Head of Medicinal Chemistry at Merck Research Laboratories, where his research focused on the design and synthesis of small-molecule antiviral compounds targeting the HIV protease, reverse transcriptase, and integrase enzymes as chemotherapeutic agents.

Dr. Young is a member of the Medicinal Chemistry Section of the American Chemical Society, AAAS, Sigma Xi, and Scientific Advisory Boards for the University of Pennsylvania and University of California, Berkeley. He has been awarded 34 U.S. patents for a variety of drug candidates. Dr. Young earned a B.S. from Stevens Institute of Technology and a Ph.D. in organic chemistry from the University of California at Berkeley.